{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:57:21Z","timestamp":1793372241663,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1038\/s41374-021-00680-9","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T02:02:54Z","timestamp":1635904974000},"page":"281-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice"],"prefix":"10.1016","volume":"102","author":[{"given":"Kota","family":"Yano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0631-046X","authenticated-orcid":false,"given":"Kanji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Seko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Okishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ishiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Tochiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seita","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiroh","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihisa","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Okanoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41374-021-00680-9_bib1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin. Proc."},{"key":"10.1038\/s41374-021-00680-9_bib2","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/nature05482","article-title":"Mechanisms linking obesity to insulin resistance and type 2 diabetes","volume":"444","author":"Kahn","year":"2006","journal-title":"Nature"},{"key":"10.1038\/s41374-021-00680-9_bib3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2119\/2007-00119.Tilg","article-title":"Inflammatory mechanisms in the regulation of insulin resistance","volume":"14","author":"Tilg","year":"2008","journal-title":"Mol. Med."},{"key":"10.1038\/s41374-021-00680-9_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/sj.ijo.0802718","article-title":"Systemic low-grade inflammation is related to both circulating and adipose tissue TNFalpha, leptin and IL-6 levels in obese women","volume":"28","author":"Maachi","year":"2004","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1038\/s41374-021-00680-9_bib5","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.2337\/dc07-0349","article-title":"Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients","volume":"30","author":"Targher","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1038\/s41374-021-00680-9_bib6","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","article-title":"Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients","volume":"54","author":"Targher","year":"2005","journal-title":"Diabetes"},{"key":"10.1038\/s41374-021-00680-9_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jhep.2017.10.016","article-title":"Fatty liver and renal function impairment - time for awareness?","volume":"68","author":"Pais","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1038\/s41374-021-00680-9_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1053\/j.gastro.2010.04.054","article-title":"Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease","volume":"139","author":"Dushay","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1038\/s41374-021-00680-9_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Investig."},{"key":"10.1038\/s41374-021-00680-9_bib10","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-0821-0","article-title":"Regulation of fibroblast growth factor 15\/19 and 21 on metabolism: in the fed or fasted state","volume":"14","author":"Guan","year":"2016","journal-title":"J. Transl. Med."},{"key":"10.1038\/s41374-021-00680-9_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tem.2014.10.002","article-title":"Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21","volume":"26","author":"Owen","year":"2015","journal-title":"Trends. Endocrinol. Metab."},{"key":"10.1038\/s41374-021-00680-9_bib12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab."},{"key":"10.1038\/s41374-021-00680-9_bib13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/09168451.2015.1135045","article-title":"Fibroblast growth factor 21 induction by activating transcription factor 4 is regulated through three amino acid response elements in its promoter region","volume":"80","author":"Maruyama","year":"2016","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"10.1038\/s41374-021-00680-9_bib14","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.2007-0313","article-title":"betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c","volume":"22","author":"Suzuki","year":"2008","journal-title":"Mol. Endocrinol."},{"key":"10.1038\/s41374-021-00680-9_bib15","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1038\/s41374-021-00680-9_bib16","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.molmet.2018.05.003","article-title":"Molecular elements in FGF19 and FGF21 defining KLB\/FGFR activity and specificity","volume":"13","author":"Agrawal","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1038\/s41374-021-00680-9_bib17","doi-asserted-by":"crossref","first-page":"e73011","DOI":"10.1371\/journal.pone.0073011","article-title":"Downstream signaling pathways in mouse adipose tissues following acute in vivo administration of fibroblast growth factor 21","volume":"8","author":"Muise","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1038\/s41374-021-00680-9_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.3892\/br.2017.890","article-title":"Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues","volume":"6","author":"Lin","year":"2017","journal-title":"Biomed. Rep."},{"key":"10.1038\/s41374-021-00680-9_bib19","doi-asserted-by":"crossref","first-page":"e8791","DOI":"10.15252\/emmm.201708791","article-title":"FGF21 gene therapy as treatment for obesity and insulin resistance","volume":"10","author":"Jimenez","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1038\/s41374-021-00680-9_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/002215549704500710","article-title":"Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues","volume":"45","author":"Hughes","year":"1997","journal-title":"J. Histochem. Cytochem."},{"key":"10.1038\/s41374-021-00680-9_bib21","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int. J. Obes."},{"key":"10.1038\/s41374-021-00680-9_bib22","doi-asserted-by":"crossref","first-page":"601290","DOI":"10.3389\/fendo.2020.601290","article-title":"FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases","volume":"11","author":"Tillman","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1038\/s41374-021-00680-9_bib23","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.28523","article-title":"Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice","volume":"64","author":"Gong","year":"2016","journal-title":"Hepatology"},{"key":"10.1038\/s41374-021-00680-9_bib24","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1038\/s41374-021-00680-9_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tem.2014.03.001","article-title":"FGF21-based pharmacotherapy\u2212potential utility for metabolic disorders","volume":"25","author":"Gimeno","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1038\/s41374-021-00680-9_bib26","doi-asserted-by":"crossref","first-page":"100057","DOI":"10.1016\/j.xcrm.2020.100057","article-title":"AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cell Rep. Med."},{"key":"10.1038\/s41374-021-00680-9_bib27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature25010","article-title":"Structures of \u03b2-klotho reveal a \u2018zip code'-like mechanism for endocrine FGF signalling","volume":"553","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"10.1038\/s41374-021-00680-9_bib28","doi-asserted-by":"crossref","first-page":"e0192146","DOI":"10.1371\/journal.pone.0192146","article-title":"LY2405319, an analog of fibroblast growth factor 21 ameliorates \u03b1-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice","volume":"13","author":"Le","year":"2018","journal-title":"PLoS One"},{"key":"10.1038\/s41374-021-00680-9_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab."},{"key":"10.1038\/s41374-021-00680-9_bib30","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1194\/jlr.M058610","article-title":"FGF21 mediates alcohol-induced adipose tissue lipolysis by activation of systemic release of catecholamine in mice","volume":"56","author":"Zhao","year":"2015","journal-title":"J. Lipid Res."},{"key":"10.1038\/s41374-021-00680-9_bib31","first-page":"1011","article-title":"Lack of fibroblast growth factor 21 accelerates metabolic liver injury characterized by steatohepatitis in mice","volume":"6","author":"Liu","year":"2016","journal-title":"Am. J. Cancer Res."},{"key":"10.1038\/s41374-021-00680-9_bib32","doi-asserted-by":"crossref","first-page":"6018","DOI":"10.1210\/en.2008-0816","article-title":"Fibroblast growth factor 21 corrects obesity in mice","volume":"149","author":"Coskun","year":"2008","journal-title":"Endocrinology"},{"key":"10.1038\/s41374-021-00680-9_bib33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2014.07.044","article-title":"Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets","volume":"147","author":"Fisher","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1038\/s41374-021-00680-9_bib34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 regulates metabolism through adipose-dependent and -independent mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab."},{"key":"10.1038\/s41374-021-00680-9_bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1124\/mol.116.104687","article-title":"A fibroblast growth factor 21-pregnane X receptor pathway downregulates hepatic CYP3A4 in nonalcoholic fatty liver disease","volume":"90","author":"Woolsey","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"10.1038\/s41374-021-00680-9_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/srep11382","article-title":"FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance","volume":"5","author":"Bernardo","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1038\/s41374-021-00680-9_bib37","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/j.gastro.2013.10.059","article-title":"Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21","volume":"146","author":"Li","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1038\/s41374-021-00680-9_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3389\/fphar.2017.00591","article-title":"Technical improvement and application of hydrodynamic gene delivery in study of liver diseases","volume":"8","author":"Huang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1038\/s41374-021-00680-9_bib39","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/hep.21655","article-title":"Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis","volume":"45","author":"Yamaguchi","year":"2007","journal-title":"Hepatology"},{"key":"10.1038\/s41374-021-00680-9_bib40","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1530\/JOE-17-0727","article-title":"FGF21 acts as a negative regulator of bile acid synthesis","volume":"237","author":"Chen","year":"2018","journal-title":"J. Endocrinol."},{"key":"10.1038\/s41374-021-00680-9_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ebiom.2016.12.016","article-title":"Chronic over-expression of fibroblast growth factor 21 increases bile acid biosynthesis by opposing FGF15\/19 action","volume":"15","author":"Zhang","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1038\/s41374-021-00680-9_bib42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A long-acting FGF21 molecule, PF-05231023, decreases body weight and improves lipid profile in non-human primates and type 2 diabetic subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab."},{"key":"10.1038\/s41374-021-00680-9_bib43","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"key":"10.1038\/s41374-021-00680-9_bib44","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2015.04.019","article-title":"Pharmacologic effects of FGF21 are independent of the \u201cbrowning\u201d of white adipose tissue","volume":"21","author":"V\u00e9niant","year":"2015","journal-title":"Cell Metab."},{"key":"10.1038\/s41374-021-00680-9_bib45","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10545-010-9061-2","article-title":"A general introduction to the biochemistry of mitochondrial fatty acid \u03b2-oxidation","volume":"33","author":"Houten","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1038\/s41374-021-00680-9_bib46","doi-asserted-by":"crossref","first-page":"e127737","DOI":"10.1172\/jci.insight.127737","article-title":"Impaired ketogenesis and increased acetyl-CoA oxidation promote hyperglycemia in human fatty liver","volume":"5","author":"Fletcher","year":"2019","journal-title":"JCI Insight"},{"key":"10.1038\/s41374-021-00680-9_bib47","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/jimd.12243","article-title":"Deficiency of 3-hydroxybutyrate dehydrogenase (BDH1) in mice causes low ketone body levels and fatty liver during fasting","volume":"43","author":"Otsuka","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1038\/s41374-021-00680-9_bib48","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1210\/en.2009-0119","article-title":"Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver","volume":"150","author":"Hotta","year":"2009","journal-title":"Endocrinology"},{"key":"10.1038\/s41374-021-00680-9_bib49","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1096\/fj.201500128","article-title":"Skeletal muscle PGC-1\u03b1 modulates systemic ketone body homeostasis and ameliorates diabetic hyperketonemia in mice","volume":"30","author":"Svensson","year":"2016","journal-title":"FASEB J."},{"key":"10.1038\/s41374-021-00680-9_bib50","doi-asserted-by":"crossref","first-page":"23505","DOI":"10.1073\/pnas.1910073116","article-title":"A single combination gene therapy treats multiple age-related diseases","volume":"116","author":"Davidsohn","year":"2019","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10.1038\/s41374-021-00680-9_bib51","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10741-020-09921-3","article-title":"Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization","volume":"25","author":"Hattori","year":"2020","journal-title":"Heart Fail. Rev."},{"key":"10.1038\/s41374-021-00680-9_bib52","doi-asserted-by":"crossref","first-page":"103415","DOI":"10.1016\/j.mcn.2019.103415","article-title":"Fibroblast growth Factor-21 promotes ketone body utilization in neurons through activation of AMP-dependent kinase. FGF21 enhances the ability of neurons to use ketone bodies","volume":"101","author":"Katsu-Jim\u00e9nez","year":"2019","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1038\/s41374-021-00680-9_bib53","doi-asserted-by":"crossref","first-page":"8430","DOI":"10.7150\/thno.44370","article-title":"Modulation of the astrocyte-neuron lactate shuttle system contributes to neuroprotective action of fibroblast growth factor 21","volume":"10","author":"Sun","year":"2020","journal-title":"Theranostics"},{"key":"10.1038\/s41374-021-00680-9_bib54","doi-asserted-by":"crossref","first-page":"1648715","DOI":"10.1155\/2017\/1648715","article-title":"Fibroblast growth factor 21 promotes C2C12 cells myogenic differentiation by enhancing cell cycle exit","volume":"2017","author":"Liu","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"10.1038\/s41374-021-00680-9_bib55","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/jcp.25735","article-title":"Fibroblast growth factor 21 (FGF21) promotes formation of aerobic myofibers via the FGF21-SIRT1-AMPK-PGC1\u03b1 pathway","volume":"232","author":"Liu","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"10.1038\/s41374-021-00680-9_bib56","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1038\/s41374-021-00680-9_bib57","doi-asserted-by":"crossref","first-page":"e123130","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"key":"10.1038\/s41374-021-00680-9_bib58","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1210\/en.2018-01056","article-title":"Fibroblast growth factor-21 controls dietary protein intake in male mice","volume":"160","author":"Larson","year":"2019","journal-title":"Endocrinology"},{"key":"10.1038\/s41374-021-00680-9_bib59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molmet.2018.03.002","article-title":"Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long-term obesogenic diet","volume":"13","author":"Singhal","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1038\/s41374-021-00680-9_bib60","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-230X-13-67","article-title":"Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress","volume":"13","author":"Yang","year":"2013","journal-title":"BMC Gastroenterol."},{"key":"10.1038\/s41374-021-00680-9_bib61","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","journal-title":"Mol. Carcinog."},{"key":"10.1038\/s41374-021-00680-9_bib62","doi-asserted-by":"crossref","first-page":"9923","DOI":"10.7150\/thno.45988","article-title":"Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling","volume":"10","author":"Zheng","year":"2020","journal-title":"Theranostics"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41374-021-00680-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41374-021-00680-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722000678?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722000678?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41374-021-00680-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:25:11Z","timestamp":1758396311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722000678"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S0023683722000678"],"URL":"https:\/\/doi.org\/10.1038\/s41374-021-00680-9","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41374-021-00680-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}